Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
John Greene, a director at CRISPR Therapeutics AG (NASDAQ:CRSP), made a significant acquisition of the company’s stock, according to a recent SEC filing. On February 26, Greene purchased 7,000 common shares at an average price of $44.85, totaling approximately $313,947. The purchase comes as the stock has experienced a notable decline of about 9% over the past week, according to InvestingPro data. This transaction was carried out in compliance with the issuer’s trading policies. Following the purchase, Greene holds a total of 7,000 shares of CRISPR Therapeutics directly. The company, currently valued at approximately $3.8 billion, maintains a strong financial position with more cash than debt on its balance sheet. InvestingPro subscribers have access to 8 additional key insights and a comprehensive Pro Research Report analyzing CRISPR Therapeutics’ financial health and market position.
In other recent news, CRISPR Therapeutics has been the focus of several analyst reports, highlighting important developments for investors. The company has seen its stock rating upgraded by Evercore ISI from In Line to Outperform, with a price target increase from $60 to $99. This optimism stems from anticipated catalysts in CRISPR’s pipeline, including in vivo programs CTX320 and CTX310, which are being closely monitored for their potential impact. Meanwhile, Citi has maintained a Buy rating on the stock, albeit with a reduced price target of $82, citing the progress of Casgevy and upcoming data releases in 2025 as significant factors.
Conversely, Stifel has taken a more cautious approach, lowering its price target to $49 while maintaining a Hold rating, due to concerns about the market uptake of Casgevy. TD Cowen also adjusted its rating from Sell to Hold, keeping the price target steady at $35, reflecting reduced downside risk. The firm’s analysis points to the need for CRISPR Therapeutics to either accelerate Casgevy’s launch or demonstrate the value of its early-stage pipeline.
These recent developments underscore a mixed outlook among analysts, with some expressing confidence in the company’s future and others maintaining a more conservative stance. The focus remains on CRISPR Therapeutics’ ability to deliver on its pipeline promises and the market’s reaction to its gene-editing therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.